Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.49 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14176505 | 0.85 | NPC1 (0.44) | SMN1; SMN2HTTMAPTTAAR1LMNA | |
| SCHEMBL22548723 | 0.83 | ALDH1A1 (0.41) | SMN1; SMN2HTTMAPTCA12CA1 | |
| SCHEMBL9595371 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2HTTMAPTCA12CA1 | |
| SCHEMBL10245176 | 0.80 | ALDH1A1 (0.53) | HTTMAPTALDH1A1KDM4EKMT2A | |
| SCHEMBL2733123 | 0.79 | CHRM2 (0.68) | TAAR1 | |
| SCHEMBL5527612 | 0.79 | CASR (0.59) | TAAR1ALDH1A1KMT2AGAA | |
| SCHEMBL5652930 | 0.78 | SMN1; SMN2 (0.59) | SMN1; SMN2HTTMAPTCA12CA1 | |
| SCHEMBL17917284 | 0.78 | NPC1 (0.40) | SMN1; SMN2HTTMAPTCA1CA2 | |
| SCHEMBL13532752 | 0.78 | NPC1 (0.56) | SMN1; SMN2MAPTCA12CA1CA2 | |
| SCHEMBL681498 | 0.78 | CHRM2 (0.61) | SMN1; SMN2HTTMAPTCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914740-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-13 | — | — | US | disclosed |
| US-9914740-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-13 | — | — | US | disclosed |
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| EP-0509005-A1 | DIPHENYLSULPHOXIMINE MUSCARINIC RECEPTOR ANTAGONISTS | Pfizer Limited (GB) | 1992-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | SMN1; SMN2 834/4885HTT 4140/4885MAPT 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.